omniture
logo
Search

/DISREGARD RELEASE: Celltrion USA/

Celltrion USA
2024-08-30 08:35 1870

We are advised by Celltrion USA that journalists and other readers should disregard the news release, Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary, issued 28-Aug-2024 over PR Newswire.

Source: Celltrion USA
Related Stocks:
Korea:068270
Media Room more

U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)

2024-12-18 11:50
883

Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Convergence 2024

2024-11-19 02:15
1373

ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)

2024-10-31 14:31
1095

Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA®  (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting

2024-10-30 03:25
1323

Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program

2024-08-13 07:46
1648

ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis

2024-05-21 12:01
1762
Related News

Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference

2024-12-27 09:44
2393

IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved

2024-12-26 17:09
2968

Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting

2024-12-25 15:42
1970
Schematic representation of the structure of QLS32015

BMG Completed Acquisition of High-Quality Assets, Marking a New Chapter in Diversified Growth

2024-12-27 22:30
1650

VISTA Eye Specialist Revolutionizes Dry Eye Treatment with Groundbreaking Research and Advanced Technology

2024-12-27 08:00
1348
An Optometrist from VISTA Eye Specialist is performing the IRPL therapy for dry eye patient.

Microtech Announces First Human Case of Implantable Microsensor for Heart Failure

2024-12-26 19:00
1068
collection